U.S. Markets closed

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
48.02-0.05 (-0.10%)
At close: 4:02PM EDT

48.02 0.00 (0.00%)
After hours: 4:02PM EDT

People also watch
NVSGSKAZNLLYNVO
Full screen
Previous Close48.07
Open48.10
Bid47.00 x 100
Ask48.66 x 10000
Day's Range47.76 - 48.23
52 Week Range36.81 - 50.24
Volume719,114
Avg. Volume1,874,947
Market Cap109.82B
Beta0.76
PE Ratio (TTM)11.61
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.64 (3.44%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com7 hours ago

    Eli Lilly: The Competition is Just Too Darn Intense!

    Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ...

  • Reuters2 days ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks5 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.